世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  遺伝子  >  多発性嚢胞腎 - パイプラインレビュー 2017年下半期

多発性嚢胞腎 - パイプラインレビュー 2017年下半期
Polycystic Kidney Disease - Pipeline Review, H2 2017

レポートタイトル 多発性嚢胞腎 - パイプラインレビュー 2017年下半期
出版社名 Global Markets Direct
発刊日 2017-10-17
体裁 PDF / 93 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 遺伝子
疾患名 多発性嚢胞腎 -
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Polycystic Kidney Disease - Overview 8
Polycystic Kidney Disease - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Polycystic Kidney Disease - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 25
Angion Biomedica Corp 25
Aptevo Therapeutics Inc 25
Celgene Corp 26
Conatus Pharmaceuticals Inc 26
DiscoveryBiomed Inc 27
Endocyte Inc 27
IC-MedTech Inc 28
Ipsen SA 28
Kadmon Corp LLC 29
Madrigal Pharmaceuticals Inc. 29
ManRos Therapeutics 30
Metabolic Solutions Development Company LLC 30
Mironid Ltd 30
NovaTarg Therapeutics Inc 31
Otsuka Holdings Co Ltd 31
Q BioMed Inc 32
Regulus Therapeutics Inc 32
XORTX Pharma Corp 32
Polycystic Kidney Disease - Drug Profiles 33
(sodium ascorbate + menadione sodium bisulfite) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ANG-3070 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CIM-2 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CR-8 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DBM-43H11 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Drug for Cystic Kidney Disease - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
EC-0371 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
IDN-8050 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
JP-153 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
lanreotide acetate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
lixivaptan - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
menadione sodium bisulfite - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
MSDC-0160 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
oxypurinol - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
pyrimethamine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
RGLS-4326 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
ricolinostat - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Inhibit PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
STA-2842 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
tesevatinib tosylate - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
TNFR x TWEAKR - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
tolvaptan - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Polycystic Kidney Disease - Dormant Projects 81
Polycystic Kidney Disease - Discontinued Products 82
Polycystic Kidney Disease - Product Development Milestones 83
Featured News & Press Releases 83
Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease 83
Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors 83
Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326 84
May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S 84
May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S. 84
Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan 85
Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD 85
Dec 06, 2016: Regulus Announces Update on RGLS4326 85
Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016 86
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 86
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 87
May 28, 2015: Otsuka’s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 88
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases 89
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 90
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 90
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Figures
Number of Products under Development for Polycystic Kidney Disease, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Number of Products by Top 10 Targets, H2 2017 17
Number of Products by Stage and Top 10 Targets, H2 2017 17
Number of Products by Top 10 Mechanism of Actions, H2 2017 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 19
Number of Products by Routes of Administration, H2 2017 21
Number of Products by Stage and Routes of Administration, H2 2017 21
Number of Products by Molecule Types, H2 2017 23
Number of Products by Stage and Molecule Types, H2 2017 23

List of Tables
Number of Products under Development for Polycystic Kidney Disease, H2 2017 9
Number of Products under Development by Companies, H2 2017 11
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Universities/Institutes, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Universities/Institutes, H2 2017 16
Number of Products by Stage and Target, H2 2017 18
Number of Products by Stage and Mechanism of Action, H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 24
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H2 2017 25
Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2017 25
Polycystic Kidney Disease - Pipeline by Celgene Corp, H2 2017 26
Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 26
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H2 2017 27
Polycystic Kidney Disease - Pipeline by Endocyte Inc, H2 2017 27
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H2 2017 28
Polycystic Kidney Disease - Pipeline by Ipsen SA, H2 2017 28
Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H2 2017 29
Polycystic Kidney Disease - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 29
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2017 30
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2017 30
Polycystic Kidney Disease - Pipeline by Mironid Ltd, H2 2017 30
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H2 2017 31
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H2 2017 31
Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H2 2017 32
Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H2 2017 32
Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp, H2 2017 32
Polycystic Kidney Disease - Dormant Projects, H2 2017 81
Polycystic Kidney Disease - Discontinued Products, H2 2017 82
Loading....